Curocell applied to the Ministry of Food and Drug Safety on the 30th for approval of its next-generation CAR-T therapy, Limkato (generic name: Anbasel). Curocell completed its approval application for the indication of relapsed and refractory large B-cell lymphoma (LBCL), based on the final report results of Limkato's clinical trials. Limkato demonstrated excellent efficacy with a complete response rate of 67.1% in its phase 2 final results. It has also secured high safety, garnering expectations as a new treatment method for patients with terminal hematological cancers. Limkato is expected to launch next year following its approval application.
Syntekabio noted on the 30th that it has applied for a patent on a "natural convection structure" that can solve the cooling issue, which is central to AI data centers. This patent, inspired by the structure of termite mounds, is designed to achieve optimal energy efficiency by utilizing airflow. The method resolves cooling issues in data centers by applying structural patents without air conditioning, significantly reducing cooling costs to one-tenth of the existing levels. Syntekabio's ABS Center has implemented a design that applies convection phenomena, where heat moves from a high-temperature area to a low-temperature one, based on termite mound structures. By optimizing the flow of external air to naturally induce heat dissipation and air circulation while minimizing separate mechanical cooling systems, the company has dramatically reduced energy consumption. It is expected to be recognized as the next-generation thermal management method due to its lower power consumption compared to existing cooling methods.
Genexine announced on the 30th that its Chinese partner, TJ Bio, has completed the Biologics License Application (BLA) for GX-H9 at the Center for Drug Evaluation (CDE) in China. GX-H9, co-developed by Genexine and Handok, is a second-generation treatment for pediatric growth hormone deficiency, applying Genexine's platform technology and improving convenience by switching from daily administration to once-weekly dosing as a biobetter new drug. Genexine explained that in the phase 3 clinical trial on pediatric growth hormone deficiency patients conducted in China, led by TJ Bio, GX-H9 demonstrated non-inferior efficacy compared to Norditropin, a first-generation daily formulation developed by Novo Nordisk, and did not cause drug side effects such as localized adiposity at the injection site or insulin resistance.
Chameditech, the aesthetic subsidiary of Cha Bio & Healthcare, announced on the 30th the launch of its HA (hyaluronic acid) filler "HyaFilia" in China. Chameditech completed local clinical trials and obtained product approval from the National Medical Products Administration (NMPA) in September. The company will enter full-scale sales after signing a supply contract with local cosmetic and plastic medical device corporations. HyaFilia is a hyaluronic acid filler developed in-house by Chameditech and has already established its presence in overseas markets by exporting to Europe, the Middle East, and other regions. Utilizing its proprietary CHA-HEART technology, it minimizes the use of BDDE, a chemical crosslinking agent, reducing cellular toxicity risks and enhancing safety.
The Remote Medical Industry Council announced on the 30th the results of its "2024 Non-Face-to-Face Medical Usage Behavior Survey," analyzing the public's behavior in utilizing non-face-to-face medical services. This year, the cumulative number of non-face-to-face medical consultations has reached approximately 11 million, representing 22% for skin diseases such as acne, atopy, and rashes; 16% for mild reimbursable treatments such as colds and flu; 12% for hair loss; 10% for chronic diseases like diabetes and hypertension; 7% for gynecological diseases, including menopausal symptom management; 6% for pediatric and adolescent care; and 4% for artificial tears. It can be seen that satisfaction with non-face-to-face medical services is high for both chronic and non-urgency diseases, as well as mild reimbursable conditions such as colds and flu. Especially in pediatrics, non-face-to-face consultations have consistently increased due to factors such as the characteristics of pediatric diseases, which can occur at all times, and the necessity of guardian accompaniment, with the highest levels of satisfaction and feedback reported after consultations. The actual number of non-face-to-face medical consultations tends to rise during the changing seasons of March-April and September-October when colds and allergic rhinitis are more prevalent. There is also an increase in users during the vacation months of July and August.